Brought to you by 
MedImmune and NGM to develop new therapies for diabetes and obesity
02 Jul 2013
Executive Summary
AstraZeneca PLC’s biologics division MedImmune LLC has teamed up with cardio and metabolic disease drug company NGM Biopharmaceuticals Inc. to discover and develop new diabetes and obesity therapeutics based on NGM’s enteroendocrine cell (EEC) platform.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MedImmune and NGM to develop new therapies for diabetes and obesity
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice